396 results about "Homeostasis" patented technology

Oxycodone formulations are provided which produce substantially flat in vivo steady state plasma profiles. Tolerance levels associated with such profiles and tolerance levels associated with biphasic profiles are shown not to be statistically different. The substantially flat in vivo steady state plasma profiles are produced by dosage forms having substantially zero order in vitro release profiles. Such release profiles produce low single dose in vivo Cmax levels which can reduce the probability of adverse side effects.

The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.

Skin conditioning compositions comprising a C4 to C30 monoalkyl-, dialkyl, monoalkanoyl- or dialkanoyl-substituted isohexide are found to exhibit a marked effect on skin hydration and barrier function homeostasis thereby improving skin appearances.

The invention specifies a method and system for leading a person suffering from “sympathetic predominance”, a specific symptom of which is “hypertension”, to breathe according to a certain pattern for the express purpose of positively altering the condition of sympathetic predominance (over activation), having the effect of bringing the autonomic nervous system into the state of balance, with consequent reductions in “tenseness”, blood pressure, muscular tightness, and emotional strain, as well as the alleviation of the myriad of subtle neuro-physiological consequences resulting from sympathetic predominance potentially including headaches, anxiety, sleep disorders, allergies, and other maladies that have yet to be attributed to this condition, thus leading to a general improvement in health, well being, and homeostasis. It accomplishes this by systematically reducing the breathing frequency with consequent increases in breathing depth, the ultimate goal being the realization and ongoing maintenance of 1 complete breathing cycle in 11.76 seconds or 5 complete breathing cycles in 58.8 seconds, the result being improved health, well being, and homeostasis.

A three-dimensional (3-D) culture “Petri-dish” for research in regenerative medicine, biotechnology and clinical translation is described. This 3-D perfusion culture dish is to advance in vitro culture tools from static 2-D to dynamic 3-D perfusion culture. Interwoven hollow fiber capillary membranes divide the “Petri-dish” culture space into a controllable 3-D pattern of different compartments, serving the functions of the organ's larger vasculature. These physically active scaffolds, which can be suitable for cell adhesion or cell aggregate immobilization, offer a supply of cells with high-performance mass exchange including gas supply and under perfusion conditions. In contrast to static and discontinuous medium supply, a dynamic culture can be achieved with continuous or alternating medium supply and integral oxygenation. They provide a more physiologic supply in the cell macro environment, including homeostasis of oxygen, pH, nutrition, soluble factors, and gradients of metabolites for the cells. Also, medium perfusion can be achieved. Consequently the invention was made for cultures at tissue density, especially stem cells and support cells, which strive to create their own stem cell niche.

Methods and compositions are provided for the protection of normal cells from cytoreductive therapy that target proliferating cells, by administering an inhibitor of Wnt signaling pathways. Wnt signaling is critically important for homeostasis of the epithelial lining of the adult intestine and other proliferating normal adult tissues.

An NMDA antagonist (such as ketamine) is administered with a safener (such as clonidine) in patients suffering from neurologic disorders other than pain. The ketamine is adminsitered at a dosage that causes slurred speech, for a span of several days. This treatment enables a patient's nervous system to return to a healthy “set point”, also called an improved stable neural homeostasis, in a manner similar to a broken bone healing itself if protected from jostling and reinjury by a cast. In at least some patients, this treatment can ease problems such as addictions to illegal or pain-killing drugs, nicotine, or alcohol, compulsive or criminal behavioral problems, severe depression, obsessive-compulsive disorders, phobias, etc. It may also provide some relief in some patients for problems such as chronic fatigue, chemical sensitivities, allergies, autoimmune disorders, and diabetes.

Ischemia-reperfusion injury commonly results from any surgical procedure requiring stopping of blood supply to an organ followed by reperfusion such as in heart bypass, angioplasty or organ transplant. The invention discloses a method to harness the innate power of repetitive transient ischemia in protecting organs against imminent ischemia-reperfusion, or any patho-physiological insults. This method of optimal remote ischemic preconditioning (ORIP) comprises of utilizing a pair of programmable pneumatic cuffs that inflate / deflate alternately occluding blood circulation to each of the limbs for pre-defined time intervals. The apparatus delivers maximal ORIP dose in shortest possible time either as an EMS procedure during patient transportation to hospital, as elective pre-surgery treatment, or in critical care for preventing multiple-organ-dysfunction-syndrome. ORIP can be self-administered and remotely monitored by clinician especially in chronic patients for homeostasis of malfunctioning target organs. ORIP may also be deployed as adjunct in angioplasty, gene / stem cell heart repair therapies.

A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy.

The subject invention provides materials and methods that effectively support innate immunity and / or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.

The ANS of a subject is continuously monitored to obtain the sympathetic nervous system (SNS) and parasympathetic nervous system (PSNS) components of the autonomous nervous system while an external stimulus is applied to the subject having a frequency that sweeps across a frequency band. The stimulus may be a vibration, flickering light or sound. The ANS is determined to have entered into a state of homeostasis when the SNS component equals the PSNS component. The value of frequency that corresponds to the state of homeostasis is selected as the fundamental frequency of the subject for use in subsequent treatment protocols.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.

Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of alerting a user associated with an infusion device delivering fluid to the body of the user involves obtaining a measurement value for a physiological condition being influenced by the fluid, obtaining a current amount of active fluid in the body of the user, determining a homeostasis metric based at least in part on the current amount of active fluid and the measurement value for the physiological condition, and generating an alert based at least in part on the homeostasis metric.

Disclosed are embryoid bodies having a uniform size of approximately 415 nm and comprising genetically modified embryonic stem cells, and methods of making same. The genetically uniform embryoid bodies can be multiplexed as one embryoid body per well in a multiwell format, and used as a high to medium throughput screen for test agents that affect the development and homeostasis of animals, including humans. The genetic modification of the embryonic stem cells is a promoter-report-selection construct that enables the selection and detection of cells of a particular lineage in the EB, to determine the effects of a test agent.

The invention discloses a CRISPR / Cas9-gRNA targeting sequence pair, a plasmid and an HD model of HTT, and relates to the field of biotechnology. The targeting sequence pair of the invention comprisesan L sequence and an R sequence. The base sequence of the L sequence is shown as SEQ ID NO.1. The base sequence of the R sequence is shown as SEQ ID NO.2. The targeting plasmid of the invention comprises a first vector plasmid and the above-mentioned targeting sequence pair. The targeting sequence pair is constructed into the first vector plasmid. The HD cell model of the invention is obtained byco-transfecting cells with PolyQ Donor plasmids and the above-mentioned targeting plasmids. By using differentiated neuron cells as a carrier to construct the HD cell model, the invention provides a research platform for exploring the influences or changes of mHtt protein on the internal environment of differentiated nerve cells, and studying the changes of various signal pathways, metabolic pathways and intracellular homeostasis caused by mHtt protein in differentiated neuronal cells.

The invention discloses a method for measuring liquid thermal conductivity coefficient and the device thereof. The invention adopts homeostasis hotline principle to measure liquid thermal conductivity coefficient. The calculation formula of the liquid thermal conductivity coefficient is used when different heat sources are applied under the condition of one dimensional conduction respectively deduced by Fourier heat conduction basic law. Then the heat generated by the heating resource which is transmitting heat. And the liquid thermal conductivity coefficient is calculated by measuring the temperature difference at particular points in heat conduction direction when heat balanced. High-temperature resistant coaxial double-layer pipes are used as outer pipes while heat stable heating tube used as inner pipes. Liquid to be measured is packed in the space between the inner and the outer pipes. The ratio of the length of the outer pipe to the external diameter of the outer pipe exceeds is greater than 10. The way of heating of the inner pipe adopts constant-temperature and uniform-speed circulating water or tempering wire and filled with high temperature resistant liquid at the same time. The former is suitable for common liquid and the latter for high temperature flammable liquid. The invention has the advantages of simple structure, large serviceable range and high accuracy rating, thus measuring the coefficients of heat conductivity of various liquids simply and precisely is possible.

This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.

The present invention presents a biocidic packaging for cosmetics and / or foodstuffs, comprises at least one insoluble proton sink or source (PSS). The packaging is provided useful for killing living target cells (LTCs), or otherwise disrupting vital intracellular processes and / or intercellular interactions of said LTC upon contact. The PSS comprises, inter alia, (i) proton source or sink providing a buffering capacity; and (ii) means providing proton conductivity and / or electrical potential. The PSS is effectively disrupting the pH homeostasis and / or electrical balance within the confined volume of the LTC and / or disrupting vital intercellular interactions of the LTCs while efficiently preserving the pH of said LTCs' environment. The present invention also discloses a method for killing living target cells (LTCs), or otherwise disrupting vital intracellular processes and / or intercellular interactions of said LTC being in a packaging, especially cosmetic or foodstuffs' packaging.

Compositions, kits and methods are provided for restoring skin barrier function to skin exposed to environmental elements and / or in a pathological condition. In general, divalent cations such as calcium ions and / or magnesium ions are included in a physiologically acceptable medium. In some embodiments, divalent cations are balanced with monovalent cations such as sodium and potassium ions at appropriate ratios in order to maintain the homeostasis of skin barrier. The compositions, kits and methods can be used as cosmetics, cosmeceuticals or pharmaceuticals for improving skin condition, and preventing or treating dermatological diseases and skin disorders.

The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles; the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

The invention relates to a method for constructing a water saving type landscape plant community, comprising the following steps of: firstly, leveling a landform of a square construction area of 20m*20m; then, arranging a #-shaped groove at a trisection position of each side of the area, horizontally laying a gravel layer at the bottom of the #-shaped groove, and backfilling plant growing soil on the gravel layer; complexly planting a mixed plant community on the plant growing soil; and finally, covering saw dust in the thickness of 10cm at a base part of trees and shrubs. The method for constructing the water saving type landscape plant community can meet the requirement on rainwater storage of the water saving type landscape plant community and homeostasis in a water community so as to achieve the purposes of reducing irrigation and saving water resources.